Chcesz wydać pracę habilitacyjną, doktorską czy monografię? Zrób to w Wydawnictwie Borgis – jednym z najbardziej uznanych w Polsce wydawców książek i czasopism medycznych. W ramach współpracy otrzymasz pełne wsparcie w przygotowaniu książki – przede wszystkim korektę, skład, projekt graficzny okładki oraz profesjonalny druk. Wydawnictwo zapewnia szybkie terminy publikacji oraz doskonałą atmosferę współpracy z wysoko wykwalifikowanymi redaktorami, korektorami i specjalistami od składu. Oferuje także tłumaczenia artykułów naukowych, skanowanie materiałów potrzebnych do wydania książki oraz kompletowanie dorobku naukowego.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Nowa Medycyna 1/2019, s. 5-11 | DOI: 10.25121/NM.2019.26.1.5
*Michał Nycz, Jakub Kropieniewicz, Kamil Suliga, Tomasz Zawadzki, Mieszko Norbert Opiłka, Zbigniew Lorenc
Peripheral blood inflammatory parameters in patients with colorectal cancer
Parametry zapalne w krwi obwodowej u chorych z rakiem jelita grubego
Department of General, Colorectal and Multiple-Organ Surgery, Faculty of Health Sciences, Medical University of Silesia in Katowice, St. Barbara Specialist Province Hospital no. 5 in Sosnowiec
Head of Department: Professor Zbigniew Lorenc, MD, PhD
Streszczenie
Wstęp. Rak jelita grubego jest trzecim najczęściej występującym nowotworem w populacji światowej. Zastosowanie coraz nowocześniejszych metod diagnostycznych i terapeutycznych powoduje spadek umieralności. Pomimo tego co roku notuje się większy odsetek zachorowalności. Parametry zapalne odgrywają istotną rolę podczas nowotworzenia – w wielu aspektach oba procesy są ze sobą połączone.
Cel pracy. Celem pracy jest przedstawienie dodatniej korelacji pomiędzy CRP i poziomem leukocytów we krwi obwodowej u chorych z RJG oraz ich porównanie z wynikiem histopatologicznym oceniającym naciek nowotworu na okoliczne tkanki lub jego brak.
Materiał i metody. Badaniem objęto 50 chorych z RJG. Czynnikami wykluczającymi były m.in. przerzuty odległe, terapia neoadjuwantowa oraz przeszłość nowotworowa. Pacjenci zostali podzieleni na dwie grupy: z naciekiem nowotworowym na okoliczne tkanki oraz bez niego.
Wyniki. U wszystkich chorych objętych badaniem zaobserwowano podwyższony poziom CRP. W grupie z naciekiem nowotworowym na okoliczne tkanki wskaźnik ten był wyższy, ale nieznamienny statystycznie. Dodatkowo w obu grupach poziom leukocytów nie przekraczał normy populacyjnej. Interesującym jest fakt, że w grupie z naciekiem nowotworowym na okoliczne tkanki poziom ten był niższy, a wartość ta okazała się być znamienna statystycznie.
Wnioski. Poziom CRP i leukocytów krwi obwodowej może być pomocny jako dodatkowy wskaźnik oceniający stopień klinicznego zaawansowania nowotworu. Ogólna dostępność i niskie koszty powyższych badań przemawiają za możliwością stosowania ich w codziennej praktyce. Obniżony poziom leukocytów u chorych z bardziej zaawansowanym procesem nowotworowym zostanie poddany dalszym badaniom.
Summary
Introduction. Colorectal cancer is the third most common cancer worldwide. The introduction of novel diagnostic and treatment methods has resulted in decreasing mortality rates; however, an increase in morbidity is observed. Severe inflammation plays an important role in many aspects associated with carcinogenesis. Neoplasia and inflammatory response are mutually related.
Aim. The aim of the study was to evaluate the association between preoperative serum C-reactive protein levels and total leukocyte count in colorectal cancer patients in comparison with postoperative histopathological findings depending on whether there was neoplastic infiltration of the local adipose tissue or not.
Material and methods. The study population included 50 patients with colon cancer. Exclusion criteria were distant metastases, neoadjuvant therapy and a past history of cancer diagnosis. Blood findings were compared with histopathology. Patients were divided into two groups – with and without neoplastic infiltration of fat tissue in histopathology.
Results. Serum C-reactive protein levels were evaluated in all patients. The tested indicator was higher in the group with infiltration, but was not statistically significant. Additionally, the WBC count was normal in both groups, but it was lower in the group with infiltration, and the result was statistically significant.
Conclusions. C-reactive protein level and total leukocyte count can be a helpful and supportive marker in staging in colorectal cancer patients. Owing to the wide availability and low cost of the above mentioned blood tests, they may be easily performed in daily medical practice. The decrease in the total leukocyte count was proportional with higher cancer stage; therefore, it needs to be further investigated.
Słowa kluczowe: RJG, parametry zapalne, wskaźnik prognostyczny
Key words: CRC, inflammatory parameters, prognostic indicator
Introduction
Colorectal cancer (CC), which is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related death globally, has become an important social problem (1). The introduction of novel diagnostic and therapeutic methods, such as combined surgical and anticancer treatment, including biological targeted therapy, has reduced mortality rates; however, since the number of newly diagnosed cases is increasing, new treatment strategies are continuously sought (2, 3). Despite the use of many determinants, with the UICC TNM staging system being the most important tool due to the varying survival time observed among patients with the same stage of disease, more sensitive markers, which will enable the introduction of appropriate, patient-tailored treatment, are still sought (4).
The extent of neoplastic infiltration and lymph node involvement are still considered one of the key prognostic factors (3). Chronic inflammation plays an important role in many aspects related to carcinogenesis, including all its stages, and affects the clinical picture (5). There is a link between neoplasia and inflammatory response: tumors may develop secondary to inflammation, and their growth may itself lead to the development of inflammatory microenvironments (6). There are a number of commonly used parameters for the evaluation of inflammatory processes, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC) and neutrophil/lymphocyte ratio (NLR) (7).
CRP is an acute phase protein produced in the liver, the expression of which is increased in inflammatory processes, promoted by the state of hypercytokinemia, increased expression of interleukins (IL)-1, IL-6 and tumour necrosis factor (TNF). The same cytokines promote tumour growth and distant metastases, and therefore play the key role in neoplastic processes (4). Changes in CRP as an inflammatory marker have been associated with the growth of many tumors, such as breast, endometrial, prostate, and ovarian cancer; however, the strongest correlations were reported for lung and colorectal cancer (8). So far, however, it has not been possible to demonstrate beyond any doubt whether the increase in CRP should be associated with the direct involvement of this protein in carcinogenesis, or whether it is only a marker of the processes involved (6). Studies in large samples using sensitive methods have shown that the increased expression of this protein is typical not only for patients with already developed cancer, but also for healthy individuals at an increased risk of cancer (6). It should be noted, however, that increased serum CRP levels were also linked to adenomas with a high risk of transformation to CC (9, 10). The above observations ale also confirmed by the evident reduction in the risk of CC due to the use of nonsteroidal anti-inflammatory drugs (8, 11).
It seems that significantly less literature reports discuss the phenomenon of increased WBC counts in the aspect of CC carcinogenesis. Ghuman et al. presented a hypothesis according to which leukocytosis is accompanied by oxygen explosion, which is associated with a sudden release of reactive oxygen species from the cell, which in turn may cause DNA damage leading to neoplastic transformation (12).
Aim
The aim of the study was to assess the correlation between peripheral blood CRP and WBC in patients with primary colorectal cancer and postoperative histology findings for the presence or absence of neoplastic infiltration of local tissues.
Material and methods
A total of 50 patients with colon cancer who were surgically treated in the Department of General, Colorectal and Multiple-Organ Surgery of the Medical University of Silesia in the period of 18 months between 2017 and 2018 were included in the study.
Inclusion criteria were age < 75 years, no cancer history or cancer dissemination to parenchymatous and peritoneal organs. Neoadjuvant therapy was also an exclusion criterion.
A total of 25 women and 25 men were qualified to this group. A total of 48 patients were admitted and underwent elective surgeries following diagnostic imaging (abdominal and pelvic CT) and diagnostic endoscopy with histopathological confirmation of cancer. Two patients underwent an urgent surgery due to life-threatening GI obstruction – no diagnostic endoscopy was performed in this small group, and the diagnosis of cancer was based on postoperative histopathological evaluation.
Laboratory samples were collected the day before surgical procedure. In addition to standard blood cell count, which importantly included WBC, CRP levels were measured. Additionally, nutritional parameters (protein, albumins, cholesterol) were measured and general condition was assessed based on the Karnofsky scale.
Histopathology involved an assessment of the tumour according to the TNM staging system, tumour ulceration, the number of sampled lymph nodes and the number of involved lymph nodes. Additionally, attention was paid to histological grade, the presence of tumour necrosis, neuronal infiltration, lymphatic/blood vessels, and oncological purity at the site of bowel separation from the mesentery.
A questionnaire to collect general information was completed by the physician responsible for treatment qualification during interviews with patients in order to increase the reliability of the results obtained.
Results

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz innych artykułów Czytelni, należy wprowadzić kod:

Kod (cena 10 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Alkady MM, Abdel-Messeih PL, Nosseir NM: Assesment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem 2018; 37: 313-319.
2. Holm M, Saraswat M, Joenväärä S et al.: Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS ONE 2018; 13(4): e0195354.
3. Yamamoto M, Saito H, Uejima C et al.: Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients. Surgery Today 2018; 48: 986-993.
4. Maeda K, Shibutani M, Otani H et al.: Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 2015; 7(8): 111-117.
5. Guo YZ, Pan L, Du CJ et al.: Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies. Asian Pacific J Cancer Prev 2013; 14(1): 243-248.
6. Allin KH, Nordestgaard BG: Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Toxicol 2011; 48(4): 155-170.
7. Seong M-K: Prognostic Inflammation Score in Surgical Patients with Colorectal Cancer. J Korean Med Sci 2015; 30: 1793-1799.
8. Prizment AE, Folsom AR, Dreyfus J et al.: Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 2013; 24: 2077-2087.
9. Lee HM, Cha JM, Lee JL et al.: High C-reactive protein level is associated with high-risk adenoma. Intest Res 2017; 15(4): 511-517.
10. Kigawa N, Budhathoki S, Yamaji T et al.: Association of plasma C-reactive protein level with the prevalence of colorectal adenoma: the Colorectal Adenoma Study in Tokyo. Nature Scientific Reports 2016; 7: 4456.
11. Cooney RV, Chai W, Franke AA et al.: C-Reactive Protein, Lipid-soluble Micronutrients, and Survival in Colorectal Cancer Patients. Cancer Epidemiol Biomarkers Prev 2013; 22(7): 1278-1288.
12. Ghuman S, Van Hemelrijck M, Garmo H et al.: Serum inflammatory markers and colorectal cancer risk and survival. Br J Cancer 2017; 116: 1358-1365.
13. Swede H, Hajduk AM, Sharma J et al.: Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer 2013; 134: 1862-1870.
14. Wang G, Can LY, Chen SH et al.: A prospective follow-up study on the association between serum level of C-reactive protein and risk of digestive system cancers in Chinese women. Zhonghua Zhong Liu Za Zhi 2016; 38(11): 876-880.
15. Song M, Wu K, Ogino S et al.: A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013; 108: 1891-1898.
16. Guo G, Chen X, He W et al.: Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS ONE 2018; 13(12): e0208547.
17. Wang X, Dai JY, Albanes D et al.: Mendelian randomization analysis of C-reactive protein on colorectal cancer risk. Int J Epidemiol 2018; 1-14.
18. Takasu C, Shimada M, Kurita N: Impact of C-reactive protein on prognosis of patients with colorectal carcinoma. Hepatogastroenterology 2013; 60(123): 507-511.
19. Toiyama Y, Fujikawa H, Koike Y et al.: Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncol Lett 2013; 5(6): 1881-1888.
20. Rasic I, Radovic S, Aksamija G: Relationship Between Chronic Inflammation and the Stage and Histopathological Size of Colorectal Carcinoma. Med Arch 2016; 70(2): 104-107.
21. Woo HD, Kim K, Kim J: Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis. Cancer Causes Control 2015; 26: 1661-1670.
22. Pathak S, Nunes QM, Daniels IR, Smart NJ: Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review. Colorectal Dis 2014; 16(10): 769-776.
23. Kersten C, Louhimo J, Ålgars A et al.: Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncologica 2013; 52(8): 1691-1698.
24. Fuji T, Tabe Y, Yajima R et al.: Elevated C-reactive protein level is associated with the tumor depth of invasion in patients with operable colorectal carcinoma. Hepatogastroenterology 2011; 58(110-111): 1470-1473.
25. Ishizuka M, Nagata H, Takagi K, Kubota K: C-Reactive Protein is Associated with Distant Metastasis of T3 Colorectal Cancer. Anticancer Res 2012; 32(4): 1409-1415.
26. Lee Y-J, Lee H-R, Nam C-M et al.: White Blood Cell Count and the Risk of Colon Cancer. Yonsei Med J 2006; 47(5): 646-656.
27. Nozoe T, Matono R, Ijichi H et al.: Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma. Int Surg 2014; 99: 512-517.
28. Sugimoto K, Komiyama H, Kojima Y et al.: Glasgow Prognostic Score as a Prognostic Factor in Patients Undergoing Curative Surgery for Colorectal Cancer. Dig Surg 2012; 29(6): 503-509.
29. Spindler KG, Demuth C, Sorensen BS et al.: Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. Tumour Biol 2018; 40(11): 1010428318811207.
otrzymano: 2019-01-09
zaakceptowano do druku: 2019-01-30

Adres do korespondencji:
*Michał Nycz
Katedra i Oddział Kliniczny Chirurgii Ogólnej, Kolorektalnej i Urazów Wielonarządowych Wydział Nauk o Zdrowiu Śląski Uniwersytet Medyczny w Katowicach. Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu
ul. Plac Medyków 1, 41-200 Sosnowiec
tel.: +48 722-167-832
michalt.nycz@gmail.com

Nowa Medycyna 1/2019
Strona internetowa czasopisma Nowa Medycyna